Synthetic biology pioneers issue bioterror warning

As synthetic biology emerges from the sidelines to produce new therapies and fuels, the burgeoning business also promises to create tools that can be put to work on the behalf of a new generation of bioterrorists. And two of the pioneers in the field, George Church and Craig Venter, warn that regulators will need to watch over the work to make sure the technology doesn't end up in the wrong hands.  Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.